Skip to main content
University of California San Francisco
UCSF School of Medicine | Department of Pediatrics UCSF Medical Center

Predictors of time to first cannulation for arteriovenous fistula in pediatric hemodialysis patients: Midwest Pediatric Nephrology Consortium study.

  • Read more about Predictors of time to first cannulation for arteriovenous fistula in pediatric hemodialysis patients: Midwest Pediatric Nephrology Consortium study.

Factors influencing the timing of initiation of renal replacement therapy and choice of modality in children with end-stage kidney disease.

  • Read more about Factors influencing the timing of initiation of renal replacement therapy and choice of modality in children with end-stage kidney disease.

Correction to: Predictors of patency for arteriovenous fistulae and grafts in pediatric hemodialysis patients.

  • Read more about Correction to: Predictors of patency for arteriovenous fistulae and grafts in pediatric hemodialysis patients.

Association between BMI changes and mortality risk in children with end-stage renal disease.

  • Read more about Association between BMI changes and mortality risk in children with end-stage renal disease.

Correction to: An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to <?6 years with chronic kidney disease receiving dialysis.

  • Read more about Correction to: An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to

Predictors of patency for arteriovenous fistulae and grafts in pediatric hemodialysis patients.

  • Read more about Predictors of patency for arteriovenous fistulae and grafts in pediatric hemodialysis patients.

An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to <?6 years with chronic kidney disease receiving dialysis.

  • Read more about An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to

Vitamin D insufficiency, hemoglobin, and anemia in children with chronic kidney disease.

  • Read more about Vitamin D insufficiency, hemoglobin, and anemia in children with chronic kidney disease.

Waist-to-height ratio, body mass index, and cardiovascular risk profile in children with chronic kidney disease.

  • Read more about Waist-to-height ratio, body mass index, and cardiovascular risk profile in children with chronic kidney disease.

COQ2 nephropathy: a treatable cause of nephrotic syndrome in children.

  • Read more about COQ2 nephropathy: a treatable cause of nephrotic syndrome in children.

Pagination

  • Previous page ‹‹
  • Page 2
  • Next page ››
Subscribe to Pediatric nephrology (Berlin, Germany)

Pediatrics Home

MAKE A GIFT

© 2026 The Regents of the University of California. The University of California San Francisco  |  UCSF Department of Pediatrics                                                                                   Accessibility  Privacy Policy  Terms of Use  A-Z Website List